Talphera Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, auditor ratification, executive compensation, and amendments to equity and stock purchase plans, with all proposals approved. No questions were raised by shareholders during the Q&A session.
-
Enrollment in the NEPHRO study surpassed 50%, with completion and top-line data expected in the second half of 2026. Cash balance was $21.1 million, with additional financing tranches available to support operations through potential Niyad approval.
Fiscal Year 2025
-
The Nephro CRRT study reached 50% enrollment, unlocking $4.1M in financing and maintaining momentum toward a second-half 2026 PMA submission. Niyad is viewed as a highly promising, simpler alternative to current CRRT anticoagulants, with strong clinical enthusiasm for adoption if approved.
-
NEPHRO study enrollment accelerated after protocol changes, but delays in activating new high-volume sites have shifted expected completion to H1 2026. Cash position and recent financing provide runway through anticipated Niyad PMA approval, with operating expenses reduced year-over-year.
-
NEPHRO study enrollment accelerated with new site strategy, reducing study size and operating expenses. Cash and expected financing should fund operations through study completion, with strong market demand for Nafamostat amid ongoing heparin and citrate shortages.
-
Q1 2025 saw reduced operating expenses and strong progress in the NEPHRO CRRT trial, with FDA-approved protocol changes and new high-volume sites accelerating enrollment. Financing is in place to support study completion by year-end, targeting NIYAD approval in 2026.
Fiscal Year 2024
-
Major protocol changes and new financing position the NEPHRO CRRT study for completion by year-end, with reduced expenses and high engagement from nephrologist-led sites expected to accelerate enrollment. FDA approval of Niyad is targeted for 2026.
-
NEPHRO CRRT trial for nafamostat is progressing with expanded clinical sites and improved enrollment processes. Q3 cash operating expenses rose to $3.5M, with $11.1M in cash on hand and additional funding likely needed before study completion.
-
Niyad, a novel anticoagulant for CRRT, is in a pivotal phase III trial with FDA breakthrough and device status, aiming for 2025 completion. The company expects strong market potential, lean commercialization, and robust IP protection, with financial support secured for ongoing operations.
-
NEPHRO study enrollment is ramping up with high-volume sites coming online, and Niyad’s commercial launch preparations are advancing. Q2 ended with $14M in cash, reduced expense guidance, and continued investor support as the company targets FDA approval and significant market potential.